Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- GPC Biotech Reports Financial Results For Third Quarter and First Nine Months of 2008
Nov 13, 2008 01:40 AM
- GPC Biotech Schedules Conference Call on November 13th to Discuss Third Quarter 2008 Financial Results
Nov 11, 2008 04:40 AM
- GPC Biotech to Present at Rodman & Renshaw Annual Global Investment Conference in New York
Nov 06, 2008 09:43 AM
- GPC Biotech Presents New Pre-Clinical Data on RGB-286638 Broad-Spectrum Kinase Inhibitor at EORTC-NCI-AACR Meeting
Oct 27, 2008 04:30 AM
- GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2008
Aug 13, 2008 01:36 AM
- GPC Biotech Schedules Conference Call on August 13th to Discuss First Half 2008 Financial Results
Aug 12, 2008 04:48 AM
- GPC Biotech Reports that Celgene to Terminate Co-Development and License Agreement for Satraplatin
Aug 06, 2008 06:02 PM
- GPC Biotech Reports That Marketing Authorization Application for Satraplatin is to Be Withdrawn
Jul 25, 2008 04:16 PM
- GPC Biotech To Re-Schedule Annual Shareholders' Meeting
Jul 17, 2008 01:43 AM
- GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
Jun 24, 2008 02:09 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
GPCB
|
Compare to S&P
|
| YTD |
-71.46 %
|
-0.01 %
|
| 4 Weeks |
-51.05 %
|
-46.43 %
|
| 12 Weeks |
-37.10 %
|
-11.00 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 3.57 %
|
|
EPS Growth in Last Year: -0.01 %
|
|
Sales Growth in Last Quarter: 486.81 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
